高级搜索

多西他赛联合ADT治疗转移性去势敏感性前列腺癌的疗效及预后因素分析

刘三河, 崔殿生, 贾全安, 段丽群, 邓康俐, 黄雷, 魏少忠

刘三河, 崔殿生, 贾全安, 段丽群, 邓康俐, 黄雷, 魏少忠. 多西他赛联合ADT治疗转移性去势敏感性前列腺癌的疗效及预后因素分析[J]. 肿瘤防治研究, 2019, 46(6): 526-531. DOI: 10.3971/j.issn.1000-8578.2019.19.0051
引用本文: 刘三河, 崔殿生, 贾全安, 段丽群, 邓康俐, 黄雷, 魏少忠. 多西他赛联合ADT治疗转移性去势敏感性前列腺癌的疗效及预后因素分析[J]. 肿瘤防治研究, 2019, 46(6): 526-531. DOI: 10.3971/j.issn.1000-8578.2019.19.0051
LIU Sanhe, CUI Diansheng, JIA Quan'an, Duan Liqun, DENG Kangli, HUANG Lei, WEI Shaozhong. Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 526-531. DOI: 10.3971/j.issn.1000-8578.2019.19.0051
Citation: LIU Sanhe, CUI Diansheng, JIA Quan'an, Duan Liqun, DENG Kangli, HUANG Lei, WEI Shaozhong. Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 526-531. DOI: 10.3971/j.issn.1000-8578.2019.19.0051

多西他赛联合ADT治疗转移性去势敏感性前列腺癌的疗效及预后因素分析

基金项目: 

国家自然科学基金 81700669

湖北省自然科学基金 2016CFB217

详细信息
    作者简介:

    刘三河(1987-),硕士,主治医师,主要从事泌尿系肿瘤疾病的临床及科研工作

    通信作者:

    魏少忠,E-mail:weishaozhong@163.com

  • 中图分类号: R737.25

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients

More Information
  • 摘要:
    目的 

    评价多西他赛联合雄激素剥夺疗法(ADT)治疗转移性去势敏感性前列腺癌(mHSPC)患者的疗效,并分析其预后影响因素。

    方法 

    回顾性分析107例mHSPC患者的临床资料,所有患者均行多西他赛联合ADT治疗,观察终点为前列腺特异性抗原无进展生存期(PSA PFS)和影像学无进展生存期(rPFS)。采用Cox单因素和多因素回归分析患者PSA PFS和rPFS的相关预后影响因素。

    结果 

    中位随访时间36月,13例患者死亡。中位PSA PFS 34.000(30.878~37.122)月,中位rPFS 33.000(30.031~35.969)月。单因素回归分析显示:初始血清PSA值、治疗7月时PSA最低值是否低于0.2 ng/dl、化疗周期数、患者体能状态评分(ECOG)、是否伴有内脏转移与患者的PSA FPS、rPFS显著相关。多因素回归分析显示:治疗7月时PSA最低值是否低于0.2 ng/dl以及是否伴有内脏转移与患者的PSA FPS、rPFS显著相关。

    结论 

    多西他赛联合ADT治疗中国mHSPC患者疗效较好,治疗7月时PSA最低值是否低于0.2 ng/dl以及是否伴有内脏转移是患者PSA FPS、rPFS的独立预后因素。

     

    Abstract:
    Objective 

    To assess the efficacy of docetaxel plus ADT on mHSPC patients and analyze the prognostic factors.

    Methods 

    We retrospectively reviewed the clinical data of 107 mHSPC patients treated with docetaxel plus ADT. Co-primary end points were PSA PFS and rPFS. Univariable and multivariable Cox analyses were performed to determine prognostic factors for PSA PFS and rPFS.

    Results 

    The median follow-up time was 36 months, and 13 (12.1%) patients died. The median PSA PFS and rPFS were 34.000 (30.878-37.122) and 33.000 (30.031-35.969) months, respectively. Univariate analysis results showed that the serum PSA, PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl), number of chemotherapy cycles (≤6 vs. 7-12), ECOG PS (0-1 vs. 2) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS. Multivariate analysis results showed that PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS.

    Conclusion 

    The effect of docetaxel plus ADT on patients with mHSPC in China is favorable. PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) are independent predictors for PSA PFS and rPFS.

     

  • 作者贡献
    刘三河:论文撰写
    崔殿生:论文设计
    贾全安:病例收集
    段丽群:统计分析
    邓康俐:统计指导
    黄雷:方案实施
    魏少忠:论文指导
  • 图  1   多西他赛联合ADT治疗mHSPC患者的PSA PFS(A)和rPFS(B)Kaplan-Meier曲线图

    Figure  1   Kaplan-Meier curves of PSA PFS(A) and rPFS(B) of mHSPC patients treated with docetaxel combined with ADT

    图  2   多西他赛联合ADT治疗第7月时PSA最低值≤0.2ng/dl与PSA最低值> 0.2ng/dl的mHSPC患者PSA PFS(A)和rPFS(B)情况比较

    Figure  2   Comparison of PSA PFS(A) and rPFS(B) of mHSPC patients with PSA nadir at 7th month ≤0.2ng/dl and > 0.2ng/dl cohorts treated with docetaxel combined with ADT

    图  3   多西他赛联合ADT治疗伴内脏转移与不伴内脏转移的mHSPC患者PSA PFS(A)和rPFS(B)情况比较

    Figure  3   Comparison of PSA PFS(A) and rPFS(B) of mHSPC patients with and without visceral cohorts treated with docetaxel combined with ADT

    表  1   107例mHSPC患者的基本情况((n)%)

    Table  1   Clinical characteristic of 107 mHSPC patients ((n)%)

    下载: 导出CSV

    表  2   多西他赛联合ADT治疗mHSPC患者预后的单因素分析

    Table  2   Univariate analysis of clinical parameters of mHSPC patients treated with docetaxel combined with ADT

    下载: 导出CSV

    表  3   多西他赛联合ADT治疗mHSPC患者预后的多因素分析

    Table  3   Multivariate analysis of clinical parameters of mHSPC patients treated with docetaxel combined with ADT

    下载: 导出CSV
  • [1]

    Sonnenburg DW, Morgans AK. Emerging Therapies in Metastatic Prostate Cancer[J]. Curr Oncol Rep, 2018, 20(6): 46. doi: 10.1007/s11912-018-0692-z

    [2]

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi: 10.3322/caac.21442

    [3]

    Corn PG, Agarwal N, Araujo JC, et al. Taxane-based Combination Therapies for Metastatic Prostate Cancer[J]. Eur Urol Focus, 2017. pii: S2405-4569(17)30265-1. https://www.sciencedirect.com/science/article/abs/pii/S2405456917302651

    [4]

    Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?[J]. Urol Clin North Am, 2017, 44(4): 611-21. doi: 10.1016/j.ucl.2017.07.008

    [5]

    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15): 1502-12. doi: 10.1056/NEJMoa040720

    [6]

    Xu L, Pachynski RK. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation[J]. Curr Urol Rep, 2018, 19(10): 79. doi: 10.1007/s11934-018-0835-7

    [7]

    Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(2): 149-58. doi: 10.1016/S1470-2045(12)70560-0

    [8]

    Nevedomskaya E, Baumgart SJ, Haendler B. Recent Advances in Prostate Cancer Treatment and Drug Discovery[J]. Int J Mol Sci, 2018, 19(5). pii: E1359. doi: 10.3390/ijms19051359

    [9]

    Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer[J]. N Engl J Med, 2015, 373(8): 737-46. doi: 10.1056/NEJMoa1503747

    [10]

    James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J]. Lancet, 2016, 387(10024): 1163-77. doi: 10.1016/S0140-6736(15)01037-5

    [11]

    Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data[J]. Lancet Oncol, 2016, 17(2): 243-56. doi: 10.1016/S1470-2045(15)00489-1

    [12]

    Cassinello J, Arranz JÁ, Piulats JM, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)[J]. Clin Transl Oncol, 2018, 20(1): 57-68. http://cn.bing.com/academic/profile?id=3bf181b728c05be1647478c3dc3d3207&encoded=0&v=paper_preview&mkt=zh-cn

    [13]

    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-32. doi: 10.3322/caac.21338

    [14]

    Attard G, Parker C, Eeles RA, et al. Prostate cancer[J]. Lancet, 2016, 387(10013): 70-82. doi: 10.1016/S0140-6736(14)61947-4

    [15]

    Chen R, Ren S, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: A collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29. doi: 10.1016/j.ajur.2014.08.007

    [16]

    Teoh JY, Ng CF, Poon DM. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective[J]. Asia Pac J Clin Oncol, 2018, 14 Suppl 5: 5-8. http://cn.bing.com/academic/profile?id=9af27577576067cf0dffd26ed6280847&encoded=0&v=paper_preview&mkt=zh-cn

    [17]

    Teoh JYC, Poon DMC, Lam D, et al. A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer[J]. Clin Genitourin Cancer, 2019. 17(1): e203-8. http://cn.bing.com/academic/profile?id=3fc0e9e00101c2a0fad1b1d5cebbdd2e&encoded=0&v=paper_preview&mkt=zh-cn

    [18]

    McNamara M, Sweeney C, Antonarakis ES, et al. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation[J]. Prostate Cancer Prostatic Dis, 2018, 21(3): 306-18. http://cn.bing.com/academic/profile?id=5fcb214f41b03d0d6588ee47d299018b&encoded=0&v=paper_preview&mkt=zh-cn

    [19]

    Gravis G, Boher JM, Joly F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial[J]. Eur Urol, 2016, 70(2): 256-62. http://cn.bing.com/academic/profile?id=f97fa273351e714eb2374345649a2b2f&encoded=0&v=paper_preview&mkt=zh-cn

    [20]

    Alhanafy AM, Zanaty F, Ibrahem R, et al. Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume[J]. Asian Pac J Cancer Prev, 2018, 19(4): 1113-8. http://cn.bing.com/academic/profile?id=f5b800c7f0e8a0c39aece45f93fb34e4&encoded=0&v=paper_preview&mkt=zh-cn

    [21]

    Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)[J]. Prostate, 2018, 78(12): 889-95. doi: 10.1002/pros.v78.12

    [22]

    Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer[J]. J Clin Oncol, 2003, 21(7): 1232-7. doi: 10.1200/JCO.2003.06.100

    [23]

    Nieder C, Haukland E, Pawinski A, et al. Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases[J]. Med Oncol, 2018, 35(4): 46. doi: 10.1007/s12032-018-1110-y

    [24]

    Francini E, Yip S, Ahmed S, et al. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy+Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer[J]. Clin Genitourin Cancer, 2018, 16(2): 130-4. doi: 10.1016/j.clgc.2017.12.012

图(3)  /  表(3)
计量
  • 文章访问数:  2278
  • HTML全文浏览量:  467
  • PDF下载量:  756
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-01-13
  • 修回日期:  2019-04-17
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2019-06-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭